The GZPS master protocol will support two independent studies, J2A-MC-GZS1 and J2A-MC-GZS2. Each study will see how well and safely orforglipron works in adult female participants with stress urinary incontinence (SUI) who have obesity or overweight. SUI is leaking urine during movement or activity such as coughing or exercising. Participation in the study will last about 58 weeks from screening to safety follow-up.

Inclusion Criteria:

• Have a body mass index (BMI) of 27 kilograms per square meter (kg/m2) or higher at screening
• Have a diagnosis of stress urinary incontinence

Exclusion Criteria:

• Have had urinary incontinence surgery
• Have recently received onabotulinumtoxin A (Botox) bladder injections or currently taking medications for urinary incontinence
• Have given birth within one year of screening
• Have had a change in body weight of more than 11 pounds within 90 days prior to screening
• Have used any anti-obesity medication or alternative weight loss remedies within 180 days prior to screening
• Have type 1 diabetes, type 2 diabetes, or any other type of diabetes
• Have had a cardiovascular health condition within 90 days prior to screening
• Are pregnant, intending to be pregnant, breastfeeding, or intending to breastfeed for the duration of the study

Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.